Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01973062 · ADVERSE EVENTS

Adverse events

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma · Source last updated 2020-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
Not reported
Other-event reporting threshold
5%
Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan

Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity. rituximab: Given IV yttrium Y 90 ibritumomab tiuxetan: Given IV

0 / 10 / 11 / 1

Group identifiers: EG000: Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    Other reported adverse events

    Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

      Complete source fields
      event Groups
      1. deaths Num Affected
        1
        deaths Num At Risk
        1
        description
        Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity. rituximab: Given IV yttrium Y 90 ibritumomab tiuxetan: Given IV
        id
        EG000
        other Num Affected
        0
        other Num At Risk
        1
        serious Num Affected
        0
        serious Num At Risk
        1
        title
        Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan
      frequency Threshold
      5

      Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

      Preserved source evidence · Not medical advice